ArticleOncology reports2018
Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells.
Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Proteomic analysis of inhibitor of apoptosis protein‑like protein‑2 on breast cancer cell proliferation.Molecular medicine reports · 2022Article
- ILP-2: A New Bane and Therapeutic Target for Human Cancers.Frontiers in oncology · 2022Review
- Overexpression of HOXD8 inhibits the proliferation, migration and invasion of breast cancer cells by downregulating ILP2 expression.Experimental and therapeutic medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the inhibitor of apoptosis protein‑like protein‑2 (ILP‑2) has been shown as a serological biomarker for breast cancer, its effect on breast cancer cell growth remains elusive. The present study aimed to determine the role of ILP‑2 in breast cancer cell growth. We used immunohistochemistry to analyze ILP‑2 expression in 59 tissue paraffin‑embedded blocks, which included 35 breast cancer tissues and 24 galactophore hyperplasia tissues. Western blot analysis was used to detect protein expression levels of ILP‑2 in breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7 as well as breast gland cell line MCF 10A. ILP‑2 was silenced by siRNA in HCC‑1937, MX‑1 and MCF‑7 cell lines. MTT assays, scratch assays and AO‑EB double staining analysis were conducted to evidence the role of ILP‑2 on breast cancer cell growth. Results from this study showed increased ILP‑2 expression in breast cancer tissues and breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7. Cell viability or rate of cell migration of HCC‑1937, MX‑1 and MCF‑7 cell lines was significantly inhibited when ILP‑2 was knocked down by siRNA. The apoptosis rate of HCC‑1937, MX‑1 and MCF‑7 cell lines was increased when compared with that of the control group. Thus, ILP‑2 plays an active role in the growth of breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.